BCL6 (B 细胞淋巴瘤 6) 是一种锌指转录抑制因子,在 B 细胞生发中心 (Germinal Center, GC) 反应中发挥关键作用。BCL6 可通过抑制 DNA 损伤检查点基因 (ATR、CHEK1、TP53),降低细胞对 DNA 损伤的应答,使 B 细胞能够在生发中心的高突变环境下持续增殖。同时,BCL6 也可通过下调细胞增殖抑制因子 (CDKN1A、PTEN) 促进 B 细胞增殖,并抑制终末分化相关基因 (IRF4、PRDM1),防止 B 细胞过早分化为浆细胞,以维持生发中心反应。此外,BCL6 还能竞争性抑制炎症信号通路 (STAT3、NF-κB),降低免疫系统的过度激活,起到抗炎作用。
BCL6 稳定表达依赖于正反馈机制,如 p300 通过抑制 HSP90 乙酰化来稳定 BCL6,而 EZH2 通过 H3K27 甲基化 进一步增强 BCL6 的转录抑制功能。
在弥漫性大 B 细胞淋巴瘤 (DLBCL)、B 细胞急性淋巴细胞白血病 (B-ALL)、慢性粒细胞白血病 (CML)、乳腺癌和非小细胞肺癌 (NSCLC) 等多种肿瘤中,BCL6 通过基因突变、染色体易位或共抑制因子异常维持癌细胞存活。因此,针对 BCL6 BTB 结构域的抑制剂可有效阻断其与共抑制因子的结合,从而抑制肿瘤生长,为恶性肿瘤的研究提供了新策略[1]。
BCL6 (B-cell lymphoma 6) is a zinc-finger transcriptional repressor that plays a crucial role in the germinal center (GC) reaction of B cells. BCL6 can promote the continuous proliferation of B cells in the highly mutagenic GC environment by suppressing DNA damage checkpoint genes (ATR, CHEK1, TP53), thereby reducing the cellular response to DNA damage. Additionally, BCL6 facilitates B cell proliferation by downregulating cell cycle inhibitors (CDKN1A, PTEN) and prevents premature differentiation into plasma cells by repressing terminal differentiation genes (IRF4, PRDM1), ensuring the maintenance of the GC reaction. Furthermore, BCL6 competitively inhibits inflammatory signaling pathways (STAT3, NF-κB), thereby reducing excessive immune activation and exerting an anti-inflammatory effect.
The stable expression of BCL6 relies on positive feedback mechanisms, such as p300-mediated inhibition of HSP90 acetylation, which stabilizes BCL6, and EZH2-catalyzed H3K27 methylation, which further enhances BCL6's transcriptional repression. In various cancers, including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), chronic myeloid leukemia (CML), breast cancer, and non-small cell lung cancer (NSCLC), BCL6 contributes to cancer cell survival through genetic mutations, chromosomal translocations, or dysregulation of co-repressors. Therefore, inhibitors targeting the BTB domain of BCL6 can effectively block its interaction with co-repressors, thereby suppressing tumor growth and providing a novel therapeutic strategy for malignant tumors[1].
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号